Stocks and Investing Stocks and Investing
Tue, August 13, 2024

Paul Choi Maintained (ASND) at Strong Buy with Increased Target to $195 on, Aug 13th, 2024


Published on 2024-10-28 13:37:10 - WOPRAI, Paul Choi
  Print publication without navigation


Paul Choi of Goldman Sachs, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Increased Target from $170 to $195 on, Aug 13th, 2024.

Paul has made no other calls on ASND in the last 4 months.



There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $140 on, Thursday, May 16th, 2024


These are the ratings of the 5 analyists that currently disagree with Paul


  • Yaron Werber of "TD Cowen" Upgraded from Hold to Strong Buy and Increased Target to $175 on, Tuesday, June 25th, 2024
  • Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $200 on, Friday, May 31st, 2024
  • Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $173 on, Wednesday, May 15th, 2024
  • Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $262 on, Friday, May 3rd, 2024
  • Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $170 on, Friday, May 3rd, 2024
Contributing Sources